Abstract 385P
Background
Introduction: Breast Cancer is one of the most common cancer in Iranian women. Whole genome association study of breast cancer have recognized various single nucleotide polymorphisms (SNPs) that are related with increased breast cancer risk in the population. This study aimed at assessing the correlation between caspase-8 (CASP8) gene polymorphisms (rs3754934 and rs12990906) and the pathogenesis of breast cancer in Northeast of Iran.
Methods
In a case- control study a total of 450 breast cancer cases and 553 healthy subjects were included in this study. Polymorphisms were genotyped by amplification-refractory mutation system (ARMS). The chi-squared test was used to calculate Odds ratio (OR) with 95% confidence interval to determine the relationship between CASP8 polymorphisms and breast cancer risk.
Results
According to the results, after adjustment for confounding factors, rs3754934 in dominant model (CA+AA vs. CC) [p = 0.004, OR = 0.49 95% CI (0.27-0.78)] and rs12990906 in allelic model (T vs. C) [p = 0.026, OR = 1.27, 95%CI (1.03-1.58)] were associated with the risk of breast cancer in this population. We did not find any association with breast cancer risk factors, clinical and pathologic features and prognosis and considered polymorphisms.
Conclusions
Polymorphisms of CASP8 gene may have a crucial role in association with the risk of breast cancer. However, further larger studies can confirm such findings. An understanding of the mode of action of these variants will aid individual-level breast cancer risk prediction.
Clinical trial identification
Editorial acknowledgement
The authors thank all participants in this research. We would also like to thank Mashhad University of Medical Sciences and Omid hospital to support the project.
Legal entity responsible for the study
Mashhad University of Medical Sciences.
Funding
Mashhad University of Medical Sciences.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract